M1RN34:BVMF
Moderna Inc Bdr
50,55 R$
0,00%
(0,00) 1 d.
5. okt., 17:08:00 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: M1RN34…
Atvērt
47,01 R$
Augsta
51,35 R$
Zema
46,36 R$
Tirgus kapitalizācija
81,13 mljrd.
Vid. apjoms
131,02 tūkst.
Apjoms
128,26 tūkst.
Augstākā 52 ned.
54,38 R$
Zemākā 52 ned.
6,02 R$
Apgrozībā esošās akcijas
399,24 milj.
Darbinieku skaits
5 tūkst.
Atvērt
47,01 R$
Augsta
51,35 R$
Zema
46,36 R$
Tirgus kapitalizācija
81,13 mljrd.
Vid. apjoms
131,02 tūkst.
Apjoms
128,26 tūkst.
Augstākā 52 ned.
54,38 R$
Zemākā 52 ned.
6,02 R$
Apgrozībā esošās akcijas
399,24 milj.
Darbinieku skaits
5 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Stock Titan
·
pirms 4 stundām
Moderna (MRNA) COO Juan Andres reports direct ownership of 125,000 common shares.
Kalkine Media
·
pirms 9 stundām
Why is Moderna (NASDAQ:MRNA) stock surging as cancer vaccine optimism builds?
TradingKey
·
pirms 9 stundām
Moderna Inc Stock (MRNA) Moved Up by 5.71% on Oct 5: What Investors Need To Know
Yahoo Finance
·
pirms 1 dienas
Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?
Profils
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
Par “Moderna Inc Bdr”
ĢenerāldirektorsStéphane Bancel
Darbinieki4,7 tūkst.
Dibināšanas datumssept. 2010
Galvenais birojs-
Sektors-
Tīmekļa vietnemodernatx.com